Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
For women receiving breast RT who develop a severe skin reaction during treatment, what is your threshold for giving a treatment break?
When do you institute a treatment break for skin reaction for patients who receive breast radiation?
Answer from: Radiation Oncologist at Community Practice
I would for symptomatic grade 3 Reaction although in era of hypofractination it is very uncommon. Sometimes would do boost RT in the break period
Sign In
or
Register
to read more
3019
Related Questions
When using surface image-guidance for breast radiation, how do you accommodate for changes in anatomy?
Does pre-chemotherapy extent of nodal involvement impact your decision to offer adjuvant radiation in cN1, ypN0 triple-negative breast cancer?
In which patients do you utilize a breast MRI as part of the initial workup for breast cancer?
Is it appropriate to use bolus with hypofractionated PMRT?
Would you consider RNI alone without CW for an isolated nodal recurrence after treatment with mastectomy and SNB for an early-stage breast cancer with no prior RT?
Does delay to the time of lumpectomy impact your decision to omit radiation?
Which patient subgroups do you plan to omit regional nodal irradiation for, given the publication of NSABP B-51?
Would you consider whole breast re-irradiation in a patient with a second/recurrent breast cancer and prior history of breast radiation therapy many years ago, if the tumor characteristics are not amenable to partial breast re-irradiation?
Would you recommend PMRT in a patient with a triple negative cT2N0, ypT2N0 metaplastic breast cancer s/p NAC, mastectomy, and SLNB?
Would you consider omitting adjuvant radiation in a very elderly patient with a small triple negative breast cancer?